Monoclonal antibody · Antagonist of HER2 (ERBB2) · developed by TransCode Therapeutics
TTX-MC138 is an antibody targeting HER2. It is being studied in HER2-positive and HER2-negative breast cancers, triple-negative breast cancer, colorectal cancer, and other solid tumors as interception therapy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06260774 | Phase 1/2 | Advanced Solid Tumor | Active not recruiting | RNAZ |
| NCT05868226 | Phase 1/2 | HER2-positive Breast Cancer | Recruiting | JAZZ |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Estrogen Receptor Positive TumorHER-2 Protein OverexpressionHER2 Mutation-Related TumorsHER2-negative Breast CancerHER2-positive Breast CancerHER2-positive Metastatic Breast CancerHormone Receptor Negative Breast CarcinomaHormone Receptor-positive Breast CancerHR PositiveMetastaticMetastatic Breast CancerMetastatic CancerProgesterone Receptor-positive Breast CancerSolid Tumor
Updated Oct 3, 2026. Something wrong or missing? Report it on the RNAZ page.
See RNAZ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RNAZ catalysts and pipeline →